N/A
Completed N=963
Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)
Hepatitis C, Chronic
Source: ClinicalTrials.gov NCT01098097 ↗
Enrolled (actual)
963
Serious AEs
1.9%
Results posted
Nov 2012
Primary outcomePrimary: Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs) — 33.6; 1.9 percentage of participants
Summary
To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs) |
33.6; 1.9 | — |
| PRIMARY Incidence of Thrombocytopenia |
3.8 | — |
| PRIMARY Incidence of Treatment Discontinuations Due to Adverse Events |
2.6; 0.1 | — |
| PRIMARY Incidence of Particular Adverse Events Resulting in Treatment Discontinuation |
0.6; 0.2; 0.2; 0.1; 0.0; 0.0 | — |
| PRIMARY Incidence of Dose Modifications Due to Adverse Events |
9.7; 0.1; 0.3 | — |
| SECONDARY Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) |
42.4 | — |
Eligibility Criteria
Inclusion Criteria
- Chronic hepatitis C of any genotype;
- Prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin did not result in a sustained virological response;
- Inclusion criteria listed on the approved label in each country;
- Willingness of the patient to participate and sign the Informed Consent Form.
Exclusion Criteria
- Patient exclusion from this observational/non-interventional study will be determined by the treating physician and will be based on the local label in each country.
Data sourced from ClinicalTrials.gov (NCT01098097). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.